Literature DB >> 19408128

Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique.

Alpaslan Tuzcu1, Serkan Yalaki, Senay Arikan, Deniz Gokalp, Mithat Bahcec, Sadiye Tuzcu.   

Abstract

The background and aim of the study is to evaluate insulin sensitivity in hyperprolactinemic subjects via euglycemic hyperinsulinemic clamp technique. Sixteen hyperprolactinemic subjects and 12 healthy subjects were included in the study. HOMA-B and HOMA-IR values of groups were calculated. Euglycemic hyperinsulinemic clamp technique was performed in both groups, and the M value of the groups was defined. Mann-Whitney U and chi-square tests were used in statistical analysis. Basal insulin level of hyperprolactinemic patients were higher than the control group (6.85 +/- 4.68; 3.66 +/- 0.88 microU/ml respectively; P < 0.05). Mean HOMA-IR and HOMA-B values of patients were higher than control group (1.49 +/- 1.30; 0.78 +/- 0.27 respectively; P = 0.02 and 136.28 +/- 72.53; 64.77 +/- 23.31, respectively, P < 0.001). M values of the patients were statistically lower than the control group (5.64 +/- 2.36; 7.05 +/- 1.62 kg/mg/min respectively; P < 0.05). (1) Hyperprolactinemic patients were more insulin resistant than control subjects. (2) Insulin resistance in hyperprolactinemic patients is not associated with obesity or anthropometric parameters such as fat content, waist circumference and BMI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19408128     DOI: 10.1007/s11102-009-0183-1

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  29 in total

Review 1.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  Decreased sensitivity to insulin in women with microprolactinomas.

Authors:  O Serri; H Beauregard; E Rasio; J Hardy
Journal:  Fertil Steril       Date:  1986-04       Impact factor: 7.329

4.  Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue.

Authors:  Louise Nilsson; Nadine Binart; Mohammad Bohlooly-Y; Margareta Bramnert; Emil Egecioglu; Jon Kindblom; Paul A Kelly; John J Kopchick; Christopher J Ormandy; Charlotte Ling; Håkan Billig
Journal:  Biochem Biophys Res Commun       Date:  2005-06-17       Impact factor: 3.575

5.  Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection.

Authors:  Trino Baptista; Emma Araujo de Baptista; Josee Lalonde; Julie Plamondon; N M K Ng Ying Kin; Serge Beaulieu; Rhida Joober; Denis Richard
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-12       Impact factor: 5.067

6.  Prolactinoma and body weight: a retrospective study.

Authors:  L B Creemers; P M Zelissen; J W van 't Verlaat; H P Koppeschaar
Journal:  Acta Endocrinol (Copenh)       Date:  1991-10

7.  Hyperprolactinemia stimulates food intake in the female rat.

Authors:  B J Moore; T Gerardo-Gettens; B A Horwitz; J S Stern
Journal:  Brain Res Bull       Date:  1986-10       Impact factor: 4.077

Review 8.  Adipocyte prolactin: regulation of release and putative functions.

Authors:  T Brandebourg; E Hugo; N Ben-Jonathan
Journal:  Diabetes Obes Metab       Date:  2007-07       Impact factor: 6.577

9.  Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo.

Authors:  G Schernthaner; R Prager; C Punzengruber; A Luger
Journal:  Diabetologia       Date:  1985-03       Impact factor: 10.122

10.  Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy.

Authors:  A B Gustafson; M F Banasiak; R K Kalkhoff; T C Hagen; H J Kim
Journal:  J Clin Endocrinol Metab       Date:  1980-08       Impact factor: 5.958

View more
  8 in total

1.  Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.

Authors:  Katarina Berinder; Thomas Nyström; Charlotte Höybye; Kerstin Hall; Anna-Lena Hulting
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

2.  Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.

Authors:  Serap Soytac Inancli; Alper Usluogullari; Yusuf Ustu; Sedat Caner; Abbas Ali Tam; Reyhan Ersoy; Bekir Cakir
Journal:  Endocrine       Date:  2012-12-12       Impact factor: 3.633

3.  Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice.

Authors:  J E de Leeuw van Weenen; E T Parlevliet; J P Schröder-van der Elst; S A van den Berg; K Willems van Dijk; J A Romijn; H Pijl
Journal:  Exp Diabetes Res       Date:  2011-04-06

4.  Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats.

Authors:  Michael Ezrokhi; Shuqin Luo; Yelena Trubitsyna; Anthony H Cincotta
Journal:  Diabetol Metab Syndr       Date:  2014-09-25       Impact factor: 3.320

Review 5.  Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas.

Authors:  Renata S Auriemma; Dario De Alcubierre; Rosa Pirchio; Rosario Pivonello; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2019-05-22       Impact factor: 5.555

6.  Prolactin Is Associated With Insulin Resistance and Beta-Cell Dysfunction in Infertile Women With Polycystic Ovary Syndrome.

Authors:  Haiyan Yang; Jie Lin; He Li; Zhangwei Liu; Xia Chen; Qianqian Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

Review 7.  Metabolic effects of prolactin.

Authors:  Rosa Pirchio; Chiara Graziadio; Annamaria Colao; Rosario Pivonello; Renata S Auriemma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-27       Impact factor: 6.055

8.  Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma.

Authors:  Ayumu Takeno; Masahiro Yamamoto; Kyoko Okazaki; Toru Yamaguchi; Toshitsugu Sugimoto
Journal:  Am J Case Rep       Date:  2016-03-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.